← Back to Staging

Integrative Oncology

Integrative & Complementary Therapies

Evidence-graded therapies and TKI drug-interaction guidance for patients on imatinib or avapritinib.

16 therapies 13 TKI interactions
For clinician use. Many supplements and foods alter CYP3A4 activity and can change tyrosine-kinase-inhibitor exposure. Evidence grades follow SIO/ASCO conventions. This summarizes published interaction data to support shared decision-making — it does not replace pharmacist review of a patient's full regimen.

Interactions with TKIs

St. John's Wort × Imatinib 400mg daily
Major Avoid

Mechanism: Potent CYP3A4 induction decreases imatinib AUC by ~30%. Concurrent use listed as contraindicated in FDA PI.

CONTRAINDICATED. St. John's Wort significantly reduces imatinib plasma levels, potentially leading to treatment failure. Discontinue at least 2 weeks before starting imatinib.

Gleevec FDA PI Section 7

St. John's Wort × Avapritinib 300mg daily
Major Avoid

Mechanism: CYP3A4 induction decreases avapritinib exposure. Strong CYP3A4 inducers reduce avapritinib AUC by ~92% per FDA PI.

CONTRAINDICATED. Strong CYP3A4 inducers like St. John's Wort reduce avapritinib AUC by approximately 92%. Discontinue before starting avapritinib.

Ayvakit FDA PI Section 7

Grapefruit × Imatinib 400mg daily
Major Avoid

Mechanism: Furanocoumarins inhibit intestinal CYP3A4, increasing imatinib bioavailability and peak plasma levels.

Avoid grapefruit and grapefruit juice. Can increase imatinib levels and exacerbate dose-dependent toxicities (edema, myelosuppression, hepatotoxicity).

Gleevec FDA PI; PMID: 15569411

Grapefruit × Avapritinib 300mg daily
Major Avoid

Mechanism: CYP3A4 inhibition by furanocoumarins increases avapritinib exposure. Moderate CYP3A4 inhibitors increase AUC by ~210% per FDA PI.

Avoid grapefruit and grapefruit juice. Can significantly increase avapritinib exposure and risk of intracranial hemorrhage.

Ayvakit FDA PI Section 7

CBD / Cannabis × Imatinib 400mg daily
Moderate Use Caution

Mechanism: CBD inhibits CYP3A4 and CYP2D6 (both involved in imatinib metabolism), potentially increasing plasma levels and toxicity risk.

Use with caution. CBD can increase imatinib levels. If patient insists on use, monitor LFTs and CBC more frequently. Consider TKI dose reduction.

PMID: 32061682

CBD / Cannabis × Avapritinib 300mg daily
Moderate Use Caution

Mechanism: CBD inhibits CYP3A4. May increase avapritinib exposure similar to moderate CYP3A4 inhibitors (~210% AUC increase per FDA PI).

Use with caution. CBD may significantly increase avapritinib levels. Monitor for cognitive effects and bleeding risk.

Ayvakit FDA PI

Green Tea / EGCG × Imatinib 400mg daily
Minor Likely Safe

Mechanism: EGCG is a moderate CYP3A4 inhibitor in vitro. Tea beverage has minimal clinical effect; concentrated supplements may modestly increase imatinib levels.

Tea beverage consumption (2-3 cups/day) is acceptable. Avoid concentrated EGCG supplements (>400mg/day) during imatinib therapy.

PMID: 19135131

Milk Thistle (Silymarin) × Imatinib 400mg daily
Minor Use Caution

Mechanism: Silymarin is a weak CYP3A4 inhibitor in vitro. Clinical studies show modest effect on CYP3A4 substrates. Theoretical hepatoprotective benefit.

Theoretical interaction. Some patients use milk thistle for imatinib-related hepatotoxicity. Monitor LFTs. Clinical significance likely low.

PMID: 17127596

Turmeric / Curcumin × Imatinib 400mg daily
Minor Likely Safe

Mechanism: High-dose curcumin inhibits CYP3A4 in vitro. Systematic review (Hosseini 2026, PMID 42067395) confirms CYP3A4-mediated interaction mechanism. Dietary turmeric has negligible effect. Supplement doses (>1g/day) may modestly affect imatinib metabolism.

Dietary turmeric in cooking is safe. High-dose curcumin supplements (>1g/day) should be used with caution. Monitor for increased imatinib side effects.

PMID: 17999464; PMID: 42067395

Echinacea × Imatinib 400mg daily
Minor Use Caution

Mechanism: Variable CYP3A4 effects reported (both induction and inhibition). Short-term use unlikely to significantly affect imatinib levels.

Short-term use (1-2 weeks for cold symptoms) is likely acceptable. Avoid prolonged daily use during imatinib therapy.

PMID: 15070161

Vitamin D × Imatinib 400mg daily
None known Recommended

Mechanism: No CYP interaction. Imatinib may contribute to bone density loss; vitamin D supplementation may be beneficial.

Supplementation recommended if 25(OH)D <30 ng/mL. Imatinib-associated hypophosphatemia and bone effects make vitamin D monitoring important.

PMID: 24732019

Melatonin × Imatinib 400mg daily
None known Likely Safe

Mechanism: Melatonin is metabolized by CYP1A2, not CYP3A4. No pharmacokinetic interaction with imatinib expected.

No known interaction. Safe for imatinib-related insomnia at 1-5mg nightly. Higher doses lack safety data.

PMID: 16229803

Ginger × Imatinib 400mg daily
None known Likely Safe

Mechanism: No significant CYP3A4 interaction. May help with imatinib-related nausea. Antiplatelet effect is mild at culinary doses.

Safe for nausea management at culinary doses and standard supplements (up to 1g/day). Stop high-dose supplements 7 days before surgery.

SIO/ASCO 2022

Interactions by Treatment Type

St. John's Wort × Systemic Therapy (all TKIs)
Major Avoid

Mechanism: Potent CYP3A4 inducer. All TKIs used in GIST are CYP3A4 substrates.

Contraindicated with all TKIs. CYP3A4 induction reduces drug levels across the entire class.

Grapefruit × Systemic Therapy (all TKIs)
Major Avoid

Mechanism: CYP3A4 inhibition increases oral bioavailability of all TKIs.

Avoid grapefruit/juice with all TKI therapy. Increases drug levels and toxicity risk.

CBD / Cannabis × Systemic Therapy (all TKIs)
Moderate Use Caution

Mechanism: CBD inhibits CYP3A4, affecting all TKI substrates.

Use with caution with any TKI. Monitor for increased toxicity if patient uses CBD.

Vitamin D × Systemic Therapy (all TKIs)
None known Recommended

Mechanism: No CYP interaction with TKIs. Bone health monitoring recommended during long-term TKI use.

Supplementation appropriate for all TKI-treated patients. Monitor 25(OH)D levels.

Acupuncture × Systemic Therapy (all TKIs)
None known Recommended

Mechanism: No pharmacologic interaction. Can help manage TKI side effects (nausea, fatigue, pain).

Safe and recommended for TKI side effect management. Ensure licensed practitioner.

Yoga & Meditation × Systemic Therapy (all TKIs)
None known Recommended

Mechanism: No pharmacologic interaction. Beneficial for fatigue, anxiety, and quality of life during TKI therapy.

Safe and recommended. Particularly beneficial for managing TKI-related fatigue and emotional distress.

Massage Therapy × Systemic Therapy (all TKIs)
None known Recommended

Mechanism: No pharmacologic interaction. Light pressure recommended if thrombocytopenic (TKI side effect).

Safe during TKI therapy. Use light pressure if platelets <100,000. Avoid deep tissue over tumor sites.

🌿 Supplements & Herbs

Astragalus

Grade D

Astragalus membranaceus — traditional Chinese medicine immune tonic. Limited CYP interaction data.

Evidence: Insufficient data on CYP3A4 interaction. Used traditionally as immune support. Exercise caution.

Potential benefit: Immune support, fatigue reduction, traditional adaptogen

⚠️ Caution: Limited safety data during TKI therapy. Discuss with oncologist. Avoid in autoimmune conditions.

MSKCC About Herbs; NCI PDQ

CBD / Cannabis

Grade B

Cannabidiol and cannabis products — increasingly popular for pain and nausea. CBD is a potent CYP3A4 inhibitor.

Evidence: CBD inhibits CYP3A4 and CYP2D6, both relevant to imatinib metabolism. Can significantly increase TKI plasma levels and toxicity.

Potential benefit: Pain management, nausea/appetite, anxiety, sleep

⚠️ Caution: CBD can significantly increase imatinib and avapritinib levels. If used, requires close TKI monitoring and possible dose adjustment. Discuss with oncologist.

PMID: 32061682; Gleevec FDA PI

Echinacea

Grade C

Echinacea purpurea — immune stimulant herb. Complex CYP effects (induces CYP3A4 in some studies).

Evidence: Variable CYP3A4 effects reported. Short-term use may be acceptable but long-term use should be avoided during TKI therapy.

Potential benefit: Immune support, cold/flu symptom reduction

⚠️ Caution: Avoid prolonged use during TKI therapy. Discuss with oncologist before use.

PMID: 15070161; MSKCC About Herbs

Ginger

Grade B

Zingiber officinale — commonly used for nausea. Mild antiplatelet activity at high doses.

Evidence: Evidence grade B for chemotherapy-induced nausea. Safe at culinary doses during TKI therapy.

Potential benefit: Anti-nausea, digestive support, anti-inflammatory

⚠️ Caution: Stop high-dose supplements 7 days before surgery due to antiplatelet effects. Culinary use is safe.

SIO/ASCO 2022; PMID: 22019308

Green Tea / EGCG

Grade C

Camellia sinensis — contains epigallocatechin gallate (EGCG). Moderate CYP3A4 inhibition potential at supplement doses.

Evidence: In vitro CYP3A4 inhibition by EGCG. Beverage consumption (2-3 cups/day) is likely safe; concentrated extracts require caution.

Potential benefit: Antioxidant, general wellness, may support cardiovascular health

⚠️ Caution: Avoid concentrated EGCG supplements (>400mg EGCG/day) during TKI therapy. Tea beverage consumption is generally acceptable.

PMID: 19135131; MSKCC About Herbs

Melatonin

Grade B

Endogenous hormone supplement for sleep. Metabolized by CYP1A2 (not CYP3A4). No significant TKI interaction expected.

Evidence: No known interaction with imatinib or avapritinib. Generally safe for cancer patients with insomnia.

Potential benefit: Sleep improvement, circadian rhythm support, antioxidant properties

⚠️ Caution: Generally safe at 1-5mg. Higher doses (>10mg) lack safety data in cancer patients.

SIO/ASCO 2022; PMID: 16229803

Milk Thistle (Silymarin)

Grade C

Silybum marianum — used for liver support. Silymarin inhibits CYP3A4 and CYP2C9 in vitro, but clinical significance with TKIs is uncertain.

Evidence: In vitro CYP3A4 inhibition. Clinical studies show modest effects. Use with caution during TKI therapy.

Potential benefit: Liver support, hepatoprotective, may help manage TKI-related hepatotoxicity

⚠️ Caution: Use with caution during imatinib/avapritinib therapy due to theoretical CYP3A4 inhibition. Discuss with oncologist.

PMID: 17127596; MSKCC About Herbs

St. John's Wort

Grade A

Hypericum perforatum — widely used herbal supplement for mild depression. Potent CYP3A4 inducer with critical drug interaction potential for TKI-treated patients.

Evidence: Strong evidence of CYP3A4 induction reducing plasma levels of imatinib and other TKIs. Contraindicated during TKI therapy per FDA labeling.

Potential benefit: Mild-to-moderate depression, anxiety, seasonal affective disorder

⚠️ Caution: CONTRAINDICATED with imatinib and avapritinib. Stop at least 2 weeks before starting TKI therapy.

Gleevec FDA PI; Ayvakit FDA PI; PMID: 10767667

Turmeric / Curcumin

Grade B

Curcuma longa — anti-inflammatory spice with CYP3A4 inhibition potential at supplemental doses. Dietary amounts are generally safe.

Evidence: In vitro CYP3A4 inhibition at high doses confirmed by systematic review (Hosseini 2026). CML-focused review validates CYP3A4 mechanism relevant to imatinib. Dietary use likely safe.

Potential benefit: Anti-inflammatory, antioxidant, may reduce treatment-related joint pain

⚠️ Caution: High-dose supplements (>1g curcumin/day) may increase TKI levels. Dietary turmeric is safe. Stop high-dose supplements before surgery.

PMID: 17999464; PMID: 42067395; MSKCC About Herbs

Vitamin C (Ascorbic Acid)

Grade C

Ascorbic acid — antioxidant vitamin. High-dose IV vitamin C may theoretically affect drug metabolism; oral doses ≤500mg/day are generally safe.

Evidence: Limited evidence of interaction with TKIs. Theoretical antioxidant interference at megadoses.

Potential benefit: Immune support, wound healing, antioxidant

⚠️ Caution: Avoid megadoses (>1g/day) during active TKI therapy. Standard dietary intake is safe.

MSKCC About Herbs; NCI PDQ

Vitamin D

Grade B

Cholecalciferol — essential vitamin frequently deficient in cancer patients. No known CYP interaction with TKIs.

Evidence: No significant drug interaction with imatinib or avapritinib. Supplementation recommended if deficient.

Potential benefit: Bone health, immune support, may reduce fatigue; deficiency common in GIST patients

⚠️ Caution: Monitor serum 25(OH)D levels. Avoid doses >4,000 IU/day without medical supervision.

PMID: 24732019; NCCN Survivorship

Vitamin E

Grade C

Alpha-tocopherol — fat-soluble antioxidant. Increases bleeding risk, relevant for surgical GIST patients.

Evidence: No direct CYP interaction with TKIs. Bleeding risk is the primary concern.

Potential benefit: Antioxidant, skin health

⚠️ Caution: Stop 2 weeks before surgery. Avoid high-dose supplementation during TKI therapy (imatinib can cause GI bleeding).

PMID: 15537682; MSKCC About Herbs

🍽️ Dietary

Grapefruit

Grade A

Citrus paradisi — contains furanocoumarins that potently inhibit intestinal CYP3A4. Can significantly increase oral TKI bioavailability.

Evidence: Strong evidence of CYP3A4 inhibition increasing TKI plasma levels. Listed in imatinib and avapritinib FDA prescribing information.

Potential benefit: Vitamin C source, general nutrition

⚠️ Caution: AVOID grapefruit and grapefruit juice during imatinib or avapritinib therapy. Also avoid Seville oranges and pomelo.

Gleevec FDA PI; Ayvakit FDA PI; PMID: 15569411

🧘 Mind–Body Practices

Acupuncture

Grade A

Traditional Chinese medicine technique using thin needles. No pharmacologic interaction with TKIs.

Evidence: SIO/ASCO Grade A recommendation for chemotherapy-induced nausea. Grade B for cancer-related pain and fatigue.

Potential benefit: Pain management, nausea reduction, fatigue improvement, stress relief

⚠️ Caution: Ensure practitioner is licensed. Avoid acupuncture at sites of lymphedema or active infection. Safe during TKI therapy.

SIO/ASCO 2022; PMID: 28874785

Massage Therapy

Grade B

Therapeutic massage for symptom management. No pharmacologic interactions with cancer treatments.

Evidence: SIO/ASCO Grade B recommendation for pain and anxiety in cancer patients.

Potential benefit: Pain relief, anxiety reduction, improved sleep, reduced muscle tension

⚠️ Caution: Avoid deep tissue massage over surgical sites or tumor areas. Light pressure if platelets low (imatinib can cause thrombocytopenia). No TKI interaction.

SIO/ASCO 2022; PMID: 28874785

Yoga & Meditation

Grade A

Mind-body practices combining physical postures, breathing exercises, and meditation. No drug interactions.

Evidence: SIO/ASCO Grade A recommendation for anxiety and mood. Grade B for fatigue and quality of life.

Potential benefit: Stress reduction, improved sleep, fatigue management, quality of life improvement

⚠️ Caution: Modify practice post-surgery. Avoid strenuous poses during early recovery. No restrictions during TKI therapy.

SIO/ASCO 2022; PMID: 28874785